Funding for this research was provided by:
Stand up To Cancer- Ovarian Cancer Research Alliance- National Ovarian Cancer Coalition Dream Team
Received: 17 May 2019
Accepted: 24 June 2019
First Online: 2 July 2019
Ethics approval and consent to participate
: This study has undergone full ethical review by the MD Anderson Cancer Center institutional review board and was approved November, 2016. Electronic informed consent shall be obtained from all patients prior to enrollment.
: Not applicable.
: DAL has received reimbursements and fees from Merck and Tesaro. DAL is holding, or currently applying for, patents for methods of early detection of ovarian cancer. All other authors declare that they have no competing interests.